Blood cancer patients who undergo donor stem cell transplants have long faced a devastating secondary threat even after their cancer is eliminated — a condition in which the very donor cells meant to save them begin attacking their own body. That threat now has a new countermeasure. The United States Food and Drug Administration has approved Tregzi, the world's first regulatory T (Treg) cell–based immunotherapy, specifically designed to improve chronic graft-versus-host disease (GVHD)–free survival in adult blood cancer patients receiving a donor stem cell transplant.
A Long-Standing Problem in Transplant Medicine
Allogeneic hematopoietic stem cell transplantation — a procedure in which blood-forming cells from a closely matched donor are infused into a patient — offers a potentially curative pathway for people diagnosed with blood cancers such as acute leukemia and myelodysplastic syndrome. However, as the FDA has noted, one of the most serious and persistent complications of this procedure is chronic GVHD, a condition in which donor immune cells recognize the recipient's healthy tissues as foreign and mount an attack against them.
Chronic GVHD can cause widespread damage across multiple organ systems and substantially reduce a patient's quality of life — even after the underlying cancer has been successfully cleared. For decades, preventing this complication rather than managing it after onset has remained one of transplant medicine's most elusive goals.
The Role of Treg Cells and How Tregzi Is Built
Tregzi was developed by California-based Orca Biosystems, Inc., and its design is rooted in the biology of regulatory T cells, or Treg cells — immune cells that play a central role in maintaining tolerance and preventing the immune system from attacking the body's own tissues. By harnessing and delivering these cells alongside other cell populations, Tregzi aims to support the rebuilding of a patient's blood and immune system after transplant while simultaneously reducing the likelihood of donor cells turning against healthy recipient tissue.
According to the FDA, Tregzi is administered following the chemotherapy conditioning regimen that prepares a patient's body to receive the transplant. The therapy is composed of three cell types drawn directly from a donor's blood: purified blood-forming stem and progenitor cells, Treg cells, and conventional T cells. All three cell populations must be obtained from an 8/8 HLA-matched donor — meaning the donor and recipient must share a high degree of genetic compatibility across eight critical immune markers. This stringent matching requirement is fundamental to the therapy's mechanism and its capacity to promote immune reconstitution while minimizing rejection.
Clinical Evidence: The PRECISION-T Trial
The FDA's approval decision is anchored in results from PRECISION-T, a randomized clinical trial that enrolled 187 adult patients diagnosed with blood cancers, including acute leukemia and myelodysplastic syndrome. Trial participants were randomly assigned to receive either Tregzi or a standard donor stem cell transplant.
The trial's primary endpoint was chronic GVHD–free survival, which the study defined as the time elapsed from transplant until either death from any cause or the first occurrence of moderate or severe chronic GVHD — whichever came first — within a two-year follow-up window.
The results were striking. According to the FDA, 78 percent of patients treated with Tregzi achieved chronic GVHD–free survival at the one-year mark, compared with only 38.4 percent of patients in the standard-transplant group. When accounting for death as a competing risk, just 12.6 percent of Tregzi-treated patients developed serious chronic GVHD within one year, versus 44 percent in the standard-transplant cohort. Based on this evidence, the FDA determined that Tregzi's benefits clearly outweigh its associated risks.
Safety Findings From the Study
The side effects observed in the PRECISION-T trial were broadly consistent with what clinicians and patients typically expect during and after stem cell transplantation procedures. Infections were the most frequently reported adverse event across the study population. Notably, no patient experienced a severe infusion reaction during the administration of Tregzi itself, and no cases of graft failure — a potentially catastrophic outcome — were recorded throughout the study period, according to the FDA.
Orca Biosystems and the FDA have advised patients and healthcare providers to consult the full prescribing information for a comprehensive account of Tregzi's safety profile and clinical considerations before initiating treatment.
Regulatory Pathway and Special Designations
The path to approval was supported by two significant regulatory designations granted to Tregzi's application. The FDA conferred both Orphan Drug designation and Regenerative Medicine Advanced Therapy (RMAT) designation on the therapy. According to the FDA, Orphan Drug designation is intended to incentivize the development of treatments for rare conditions, while RMAT designation is designed to accelerate the development and review process for regenerative therapies that show early promise in addressing serious or life-threatening diseases.
These designations reflect the agency's recognition of the unmet medical need in the chronic GVHD space and its confidence in the innovative nature of Treg cell–based treatment as an emerging therapeutic category.
FDA Official Describes the Approval's Significance
Karim Mikhail, Acting Director of the FDA Center for Biologics Evaluation and Research, described the approval as representing a genuinely new direction in cellular therapy. Mikhail stated that chronic GVHD has historically been among the most feared and difficult-to-prevent complications for patients requiring stem cell transplantation, and that the clearance of Tregzi offers a meaningful new option that can support immune system reconstitution while substantially lowering that risk. He added that the approval reflects the broader promise of what cellular therapies can deliver for this patient population.
By the Numbers
- 187 — adult blood cancer patients enrolled in the PRECISION-T randomized clinical trial
- 78% — proportion of Tregzi-treated patients who achieved chronic GVHD–free survival at one year
- 38.4% — proportion of standard-transplant patients who met the same outcome at one year
- 12.6% — share of Tregzi patients who developed serious chronic GVHD within one year
- 44% — share of standard-transplant patients who developed serious chronic GVHD within one year
- 8/8 — number of HLA immune markers required to match between donor and recipient for Tregzi eligibility
- 2 years — follow-up period used to define and measure chronic GVHD–free survival in the trial
Why This Matters
Tregzi's approval marks a historic first — no Treg cell–based immunotherapy has ever before received regulatory clearance anywhere in the world, opening an entirely new class of cellular treatment for one of transplant medicine's most difficult-to-solve complications. The PRECISION-T trial data, as reported by the FDA, show that Tregzi more than doubled the rate of chronic GVHD–free survival at one year compared with standard transplantation, giving blood cancer patients a substantially improved chance of recovering without this debilitating condition. The dual designation of Tregzi as both an Orphan Drug and a Regenerative Medicine Advanced Therapy further underscores the urgency the FDA has placed on advancing treatments for patients who, until now, had limited options for preventing chronic GVHD before it took hold.
Source: Originally reported by wire reports